Drug/Small Molecule:
etonogestrel

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • etonogestrel
Trade Names
  • Implanon
Brand Mixture Names
  • Nuvaring (Ethinyl Estradiol + Etonogestrel)

PharmGKB Accession Id:
PA164771231

Description

Etonogestrel is a molecule used in hormonal contraceptives, most notably the subdermal implant Implanon. Wikipedia

Source: Drug Bank

Indication

For use as a female contraceptive (depot).

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Etonogestrel binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like etonogestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.

Source: Drug Bank

Pharmacology

Etonogestrel is used as a female contraceptive. Etonogestrel is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Etonogestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.|Avoid excessive quantities of coffee or tea (Caffeine).|Take with food.|Take at the same time everyday.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic.

Source: Drug Bank

Half-Life

25 hours

Source: Drug Bank

Toxicity

Symptoms of overdose include nausea, vomiting, vaginal bleeding, and other menstrual irregularities.

Source: Drug Bank

Route of Elimination

Excretion of ENG and its metabolites, either as free steroid or as conjugates, is mainly in urine and to a lesser extent in feces.

Source: Drug Bank

Volume of Distribution

  • 201 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C22H28O2

Source: Drug Bank

Isomeric SMILES

CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34

Source: Drug Bank

CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C#C

Source: Drug Bank

Canonical SMILES

[H][C@@]

Source: Drug Bank

Average Molecular Weight

324.4565

Source: Drug Bank

Monoisotopic Molecular Weight

324.20893014

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Drug Targets

Gene Description
ESR1 (source: Drug Bank)
PGR (source: Drug Bank)

Drug Interactions

Drug Description
etonogestrel Thiopental may decrease the effect of Etonogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. (source: Drug Bank)
etonogestrel Thiopental may decrease the effect of Etonogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. (source: Drug Bank)
etonogestrel Oral Tretinoin may decrease the effect of oral contraceptive, Etonogestrel. An alternate form of contraception should be used during concomitant therapy. (source: Drug Bank)
etonogestrel Etonogestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if etonogestrel is initiated, discontinued or dose changed. (source: Drug Bank)
No related diseases are available

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0052-0272-01
DrugBank:
DB00294
ChEBI:
50777
PubChem Compound:
40976
PubChem Substance:
181766
Drugs Product Database (DPD):
2253186
Therapeutic Targets Database:
DAP000855
FDA Drug Label at DailyMed:
50ed7e31-b9b7-4f0a-8e36-91ed5af86b81

Clinical Trials

These are trials that mention etonogestrel and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.